Citations

Clear

65 citation(s) found for "Tepper, SJ".

Rimegepant 75 mg Provides Early and Sustained Relief of Migraine With a Single Dose: Results from 3 Phase 3 Clinical Trials (2366)
Pavlović, Jelena , Tepper, Stewart J. , Stock, Elyse, Thiry, Alexandra, Conway, Charles M., Jensen, Christopher, Morris, Beth , Coric, Vladimir, Croop, Robert , Pavlovic, Jelena M. , Dodick, David W. , Friedman, Deborah I. , Newman, Lawrence C. , Lipton, Richard B.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2366 Get It

Benefit of Migraine Prevention with Erenumab in Patients Receiving Background Standard-of-care Acute Treatment (1381)
Starling, Amaal J. , Tepper, Stewart J. , Bernstein, Carolyn , Chou, Denise E. , Ailani, Jessica , Zhang, Feng , Lima, Gabriel Paiva da Silva

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1381 Get It

Cardiovascular Safety of Erenumab in Patients with Migraine and Aura (1209)
Tepper, Stewart J. , Xue, Fei , Olearczyk, J, Ashina, Messoud , Goadsby, Peter J. , Dodick, David W. , Zhang, Feng , Olearczyk, Jeffrey, Lima, Gabriel Paiva da Silva

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1209 Get It

Real-World Healthcare Costs and Resource Utilization Among Patients Treated With Erenumab in the United States: A Retrospective Claims Database Study (P16-7.003)
Tepper, Stewart J. , Vo, Pamela, Joshi, Parth, Abdrabboh, Ahmad, Ferraris, Matias, Tiwari, Santosh , Schwedt, Todd J. , Glassberg, Mrudula B. , Tiwari, Santosh, Thompson, Jeffrey A.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.394 Get It

A Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM) (P11-2.005)
Kuruvilla, Deena E. , Starling, Amaal J. , Tepper, Stewart J. , Mann, J. John , Panza, Gregory A. , Johnson, Michael L.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2994 Get It

Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non‐interventional study using claims data from the United States
Tepper, Stewart J. , Vo, Pamela, Joshi, Parth, Abdrabboh, Ahmad, Ferraris, Matias, Tiwari, Santosh , Schwedt, Todd J. , Thompson, Jeffrey A. , Tiwari, Santosh

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 1, 2023 | Volume: 63 | Issue: 10 | Pages: 1423-1436

10.1111/head.14612 | PMID 37655551 Get It

Abstract Objective To assess healthcare costs and healthcare resource utilization (HCRU) among adult patients who newly initiated erenumab in the United States. Methods This retrospective, non‐interventional analysis included adult patients (aged ≥18 years) newly initiating erenumab and who had three consecutive monthly claims for erenumab (11/1/2017–9/1/2019) from the Komodo Health database. Outcomes included migraine‐related and all‐cause costs, use of other preventive/acute migraine medications, and HCRU. All outcomes were compared during the 180‐day pre‐ versus the 180‐day post‐index periods. Cost outcomes were also assessed for longer periods including post‐index Days 91–270 and monthly mean post‐index costs for the longest time of continuous insurance enrollment. Results Overall, 1839 patients with migraine were included for analysis. Compared to the 180‐day pre‐index period, an increase in total migraine‐related costs (+$2639; p < 0.0001), migraine‐related prescription costs (+$3435, p < 0.0001), all‐cause total costs (+$2977; p < 0.001), and all‐cause prescription costs (+$4102; p < 0.0001) were observed during the 180‐day post‐index period after adjusting for covariates. Conversely, reduction in migraine‐related medical costs (−$896; p < 0.0001), and significantly lower odds of migraine‐related emergency room visits (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.44–0.82; p = 0.001), migraine‐related office visits (OR 0.58, 95% CI 0.53–0.64; p < 0.0001), and migraine‐related neurologist visits (OR 0.69, 95% CI 0.63–0.75; p < 0.0001) were observed during the 180‐days post‐index period. There were significant decreases in the odds of having overall preventive migraine medications (OR 0.81, 95% CI 0.75–0.87; p < 0.0001), acute‐migraine medications (OR 0.92, 95% CI 0.85–1.00; p = 0.038), and triptan (OR 0.79, 95% CI 0.73–0.85; p < 0.0001) during the 180‐day post‐index period. Sensitivity analyses on cost outcomes found no statistically significant differences in pre‐index migraine‐related costs compared to post‐index migraine‐related costs when assessing longer post‐index follow‐up periods. Conclusion Initiation of therapy with a novel treatment is often associated with an increase in overall healthcare costs due to the entrance costs associated with novel therapy. For a chronic condition such as migraine, cost versus health benefits should be evaluated over a long period (e.g., ≥2 years) to better understand the true benefits of therapy. Data from this study suggest that the entrance cost for erenumab, the primary driver of the high post‐index prescription costs gets mitigated by reduced medical costs over long‐term follow‐up. The results indicate better disease management in adult patients with migraine, which should be an important consideration for both patients and payors, as these findings have shown an offset between migraine‐related prescription and medical costs.
Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study
Kim, Hannah P. , Singal, Amit G. , Owen, Dawn , Parikh, Neehar D. , Rose, Steven C., McGinty, Katrina , Agala, Chris B. , Burke, Lauren M. , Abate, Anjelica, Do, John, Folkert, Michael R. , Forbes, C.D., Hattangadi‐Gluth, Jona A. , Hayashi, Paul H. , Jones, Keri, Lawrence, Theodore S. , Maurino, C. , Mayo, Charles S. , Pak, Taemee , Patil, Preethi, Simpson, Daniel R. , Tepper, Joel E. , Thapa, Diwash , Moon, Andrew M , Singal, Amit , Owen, Dawn , Parikh, Neehar D , McGinty, Katrina A , Burke, Lauren M , Altun, Ersan , Folkert, Michael R , Hayashi, Paul H , Khatri, Gaurav , Kono, Yuko , Lawrence, Theodore S , Tepper, Joel E , Gerber, David A , Mendiratta-Lala, Mishal , Beyer, Christian, Forbes, Chalon, Khatri, Gaurav , Mauro, David M. , Sanders, Emily C. , Yanagihara, Ted K. , Wang, Kyle , Gerber, David A.

Mayo Clinic

Hepatology Communications | June 14, 2023 | Volume: 7 | Issue: 7 | Pages: No page available

10.1097/hc9.0000000000000184 | PMID 37314737 Get It

Background & Aims: Early-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with ablation or SBRT in a multicenter, US cohort. Approach & Results: We included adult patients with treatment-naïve HCC lesions without vascular invasion treated with thermal ablation or SBRT per individual physician or institutional preference from January 2012 to December 2018. Outcomes included local progression after a 3-month landmark period assessed at the lesion level and overall survival at the patient level. Inverse probability of treatment weighting was used to account for imbalances in treatment groups. The Cox proportional hazard modeling was used to compare progression and overall survival, and logistic regression was used for toxicity. There were 642 patients with 786 lesions (median size: 2.1 cm) treated with ablation or SBRT. In adjusted analyses, SBRT was associated with a reduced risk of local progression compared to ablation (aHR 0.30, 95% CI: 0.15–0.60). However, SBRT-treated patients had an increased risk of liver dysfunction at 3 months (absolute difference 5.5%, aOR 2.31, 95% CI: 1.13–4.73) and death (aHR 2.04, 95% CI: 1.44–2.88, p < 0.0001). Conclusions: In this multicenter study of patients with HCC, SBRT was associated with a lower risk of local progression compared to thermal ablation but higher all-cause mortality. Survival differences may be attributable to residual confounding, patient selection, or downstream treatments. These retrospective real-world data help guide treatment decisions while demonstrating the need for a prospective clinical trial.
Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis
Tepper, Stewart J. , Kudrow, David, Ashina, Messoud , Reuter, Uwe , Dodick, David W. , Wang, Andrea , Cheng, Sunfa , Klatt, Jan , Mikol, Daniel D., Ashina, Messoud , Dodick, David W , Reuter, Uwe , Lipton, Richard B. , Silberstein, Stephen D.

Mayo Clinic

Headache: The Journal of Head and Face Pain | June 14, 2023 | Volume: 63 | Issue: 6 | Pages: 730-742

10.1111/head.14536 | PMID 37313616 Get It

Abstract Objective Assess the long‐term efficacy and safety of erenumab in patients with chronic migraine with acute medication overuse. Background Overuse of acute medication in patients with chronic migraine has been linked to greater pain intensity and disability and may diminish the effectiveness of preventive therapies. Methods This 52‐week open‐label extension study followed a 12‐week double‐blind placebo‐controlled study in which patients with chronic migraine were randomized 3:2:2 to placebo or once‐monthly erenumab 70 mg or 140 mg. Patients were stratified by region and medication overuse status. Patients received erenumab 70 mg or 140 mg throughout or switched from erenumab 70 to 140 mg (based on protocol amendment to augment safety data at higher dose). Efficacy was assessed in patients with and without medication overuse at parent study baseline. Results Of 609 patients enrolled in the extension study, 252/609 (41.4%) met the criteria for medication overuse at parent study baseline. At Week 52, the mean change in monthly migraine days from parent study baseline was −9.3 (95% confidence interval: −10.4, −8.1 days) in the medication overuse subgroup versus −9.3 (−10.1, −8.5 days) in the non‐medication overuse subgroup (combined erenumab doses); proportion of patients achieving ≥50% reduction in monthly migraine days at Week 52 was 55.9% (90/161; 48.2%, 63.3%) versus 61.3% (136/222; 54.7%, 67.4%), respectively. Among baseline users of acute migraine‐specific medication, the mean change in monthly migraine‐specific medication days at Week 52 was −7.4 (−8.3, −6.4 days) in the medication overuse subgroup versus −5.4 (−6.1, −4.7 days) in the non–medication overuse subgroup. Most patients (197/298; 66.1%) in the medication overuse subgroup transitioned to non‐overuse status by Week 52. Erenumab 140 mg was associated with numerically greater efficacy than erenumab 70 mg across all endpoints. No new safety signals were identified. Conclusion Long‐term erenumab treatment demonstrated sustained efficacy and safety in patients with chronic migraine with and without acute medication overuse.
Country-level gender inequality is associated with structural differences in the brains of women and men
Alliende, Luz María , Medel, Vicente , Bethlehem, Richard A. I. , Ringlein, Grace , Arango, Celso , Asmal, Laila , Bellgrove, Mark A. , Bernardo, Miquel , Billeke, Pablo , Bosch‐Bayard, Jorge , Busatto, Geraldo F. , Castro, Mariana N. , Chaim-Avancini, Tiffany , Compte, Albert , Costanzi, Monise , Dazzan, Paola , Fuente‐Sandoval, Camilo de la , Díaz‐Zuluaga, Ana M. , Duran, Fábio , Fittipaldi, Sol , Fornito, Alex , Freimer, Nelson B. , Gadelha, Ary , Gama, Clarissa Severino , Ramesh, Ranjini Garani , García‐Rizo, Clemente , Campo, Cecilia González , González‐Valderrama, Alfonso , Holla, Bharath , Ibáñez, Agustín , Ivanovic, Daniza , Jackowski, Andrea Parolin , Löchner, Christine , López‐Jaramillo, Carlos , Massuda, Raffael , McGuire, Philip , Murray, Robin , Özerdem, Ayşegül , Pan, Pedro Mário , Parellada, Mara , Phahladira, Lebogan, Ramírez-Mahaluf, Juan Pablo , Reyes-Madrigal, Francisco , Roos, Annerine , Scheffler, Freda , Stein, Dan J. , Tepper, Ángeles , Ueno, Tsukasa, Undurraga, Juan , Valli, Isabel , Villarreal, Mirta F. , Yalın, Nefize , Zamorano, Francisco , Zanetti, Marcus V. , cVEDA, Pine, Daniel S. , Evans‐Lacko, Sara , Crossley, Nicolás , Murthy, Pratima , Chakrabarti, Amit , Basu, Debasish , Subodh, B. N., Singh, Lenin, Singh, Roshan Lourembam, Kalyanram, Kartik , Kartik, Kamakshi, Kurpad, Sunita Simon , Bharath, Rose Dawn , Orfanos, Dimitri Papadopoulos , Sharma, Eesha , Alliende, Luz María , Medel, Vicente , Bethlehem, Richard A I , Benegal, Vivek , Bernardo, Miquel , Billeke, Pablo , Busatto, Geraldo F , Castro, Mariana N , Czepielewski, Leticia , de la Fuente-Sandoval, Camilo , Duran, Fabio L S , Fittipaldi, Sol , Fornito, Alex , Garani, Ranjini , Guinjoan, Salvador , Ibañez, Agustín , Ivanovic, Daniza , Lochner, Christine , Massuda, Raffael , Miyata, Jun , Mizrahi, Romina , Murray, Robin , Ramirez-Mahaluf, Juan P , Reis Marques, Tiago , Reyes-Madrigal, Francisco , Roos, Annerine , Salum, Giovanni , Stein, Dan J , Tepper, Angeles , Undurraga, Juan , Undurraga, Eduardo A , Valdes-Sosa, Pedro , Valli, Isabel , Zamorano, Francisco , Crossley, Nicolas A , López-Jaramillo, Carlos , Ozerdem, Aysegul , Yalin, Nefize , Zugman, André , Seidlitz, Jakob , Arnatkevičiūtė, Aurina , Bressan, Rodrigo A. , Forti, Marta Di , Díaz‐Caneja, Covadonga M. , Plessis, Stefan S. du , León-Ortíz, Pablo , Luckhoff, Hilmar Klaus , Phahladira, Lebogang , Reckziegel, Ramiro de Freitas Xavier , Rosa-Neto, Pedro , Serpa, Maurício Henriques , Winton‐Brown, Toby , cVEDA, Winkler, Anderson M. , Kartik, Kamakshi , Kumaran, Kalyanaraman , Krishnaveni, Ghattu Vedamurthy , Kuriyan, Rebecca , Barker, Gareth J. , Desrivières, Sylvane , Purushottam, Meera , Hickman, Matthew , Heron, Jon , Toledano, Mireille B. , Vaidya, Nilakshi

Mayo Clinic

Proceedings of the National Academy of Sciences | May 8, 2023 | Volume: 120 | Issue: 20 | Pages: No page available

10.1073/pnas.2218782120 | PMID 37155867 Get It

Gender inequality across the world has been associated with a higher risk to mental health problems and lower academic achievement in women compared to men. We also know that the brain is shaped by nurturing and adverse socio-environmental experiences. Therefore, unequal exposure to harsher conditions for women compared to men in gender-unequal countries might be reflected in differences in their brain structure, and this could be the neural mechanism partly explaining women’s worse outcomes in gender-unequal countries. We examined this through a random-effects meta-analysis on cortical thickness and surface area differences between adult healthy men and women, including a meta-regression in which country-level gender inequality acted as an explanatory variable for the observed differences. A total of 139 samples from 29 different countries, totaling 7,876 MRI scans, were included. Thickness of the right hemisphere, and particularly the right caudal anterior cingulate, right medial orbitofrontal, and left lateral occipital cortex, presented no differences or even thicker regional cortices in women compared to men in gender-equal countries, reversing to thinner cortices in countries with greater gender inequality. These results point to the potentially hazardous effect of gender inequality on women’s brains and provide initial evidence for neuroscience-informed policies for gender equality.
Interim Analysis of Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study (P13-12.004)
Tepper, Stewart J. , Starling, Amaal J. , Albrecht, Detlef

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202439 Get It